We need an instrument that is sensitive and specific
modification (where medications were eliminated) resulted in improved discrimination compared with the cSFI.
Some may have a contrary opinion, asking why any rule should be used to determine flare severity; as physician judgment of flares and rating them as mild, moderate, severe or even inconsequential may suffice, or using a scale such as a physician VAS of flare, where training could occur for evaluators within a trial.
Measurement of flare is important in clinical trials, as is measurement of improvement, and the two may not be scaled to detect important differences between groups in a study. The SLE responder index (SRI) was developed for measuring improvement in SLE trials. The SRI requires a 54 point decrease in SELENA-SLEDAI score (improvement), no new BILAG A and no more than one new BILAG B score (i.e. no major organ worsening, although there can be some worsening) and no worsening of the physician global assessment (i.e. 40.3 point worsening out of 3) [6] . Ideally the percentage of flare would be [100 À percentage responding À percentage with no flare and no response] and the percentage responding would be (1 À percentage flaring À percentage without a response or flare). The SFI has a problem partially due to the SLEDAI, where an organ-specific flare can become much worse and not be considered a more severe flare. For instance, significant worsening of renal, muscle, joint, skin, serositis, CNS, cytopenias and serology would not score higher if present already.
Determining increases or decreases in steroids may be an important outcome in SLE trials (i.e. finding a treatment with steroid-sparing effects is desirable), but the eSFI does not account for treatment changes. However, this can be captured in studies if steroids are part of the outcome measurements (percentage that reduce or increase steroids by a certain amount). Potential insensitivity to improvement or relevant worsening of the SLEDAI may have resulted in negative treatment differences where important differences may have been present, whereas many BILAG flares were not considered flares by the physician. Dichotomous outcomes in the SLEDAI lose sensitivity (a feature is present or absent) and there is not incremental change within organs [4, 5, 7] .
SLE studies have used instruments that were either insensitive to changes in flaring and improving or had many flares detected (several of which were clinically not relevant) and thus non-specific. Perhaps a composite scoring system that is specific (detects real but major flares) but insensitive is not the best way to evaluate worsening/flaring in SLE.
In clinical trials and in following up patients there needs to be sophisticated techniques for analysing patients if they have flared more than once. There can be a flare rate per patient, mean change per patient, only the first flare counted, etc. These issues have not been standardized for most rheumatological diseases, such as counting digital ulcers in SSc (number of new ulcers, number of ulcers per patient, total ulcer burden, time to first ulcer or healing, etc.) [8] . Different analyses can vary the interpretation of treatment efficacy. Data for flares in SLE are often skewed when a minority have multiple flares. This is also true for radiographic progression in RA biologic trials, where 15% progress radiographically and thus mean Xray change is not an accurate representation of the data, whereas the percentage progressing over a certain threshold change may be [9] .
Therefore the article by Thanou et al. [1] can help trialists determine whether to include a responder and flare index and to use the SFI with or without the proposed modifications. However, relevant flares in organs with pre-existing disease activity will not be detected, so, in order to understand therapy in SLE, we need a finely tuned instrument to detect both improvements and flares that are clinically important. 
